524 related articles for article (PubMed ID: 24146797)
1. Podocalyxin-like protein is expressed in glioblastoma multiforme stem-like cells and is associated with poor outcome.
Binder ZA; Siu IM; Eberhart CG; Ap Rhys C; Bai RY; Staedtke V; Zhang H; Smoll NR; Piantadosi S; Piccirillo SG; Dimeco F; Weingart JD; Vescovi A; Olivi A; Riggins GJ; Gallia GL
PLoS One; 2013; 8(10):e75945. PubMed ID: 24146797
[TBL] [Abstract][Full Text] [Related]
2. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
3. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
[TBL] [Abstract][Full Text] [Related]
4. A Sox2:miR-486-5p Axis Regulates Survival of GBM Cells by Inhibiting Tumor Suppressor Networks.
Lopez-Bertoni H; Kotchetkov IS; Mihelson N; Lal B; Rui Y; Ames H; Lugo-Fagundo M; Guerrero-Cazares H; Quiñones-Hinojosa A; Green JJ; Laterra J
Cancer Res; 2020 Apr; 80(8):1644-1655. PubMed ID: 32094299
[TBL] [Abstract][Full Text] [Related]
5. The transcript ENST00000444125 of lncRNA LINC01503 promotes cancer stem cell properties of glioblastoma cells via reducing FBXW1 mediated GLI2 degradation.
Wei P; Jiang J; Xiao M; Zeng M; Liu X; Zhao B; Chen F
Exp Cell Res; 2022 Mar; 412(1):113009. PubMed ID: 34990616
[TBL] [Abstract][Full Text] [Related]
6. Functional genomics analyses of RNA-binding proteins reveal the splicing regulator SNRPB as an oncogenic candidate in glioblastoma.
Correa BR; de Araujo PR; Qiao M; Burns SC; Chen C; Schlegel R; Agarwal S; Galante PA; Penalva LO
Genome Biol; 2016 Jun; 17(1):125. PubMed ID: 27287018
[TBL] [Abstract][Full Text] [Related]
7. Bmi1 regulates human glioblastoma stem cells through activation of differential gene networks in CD133+ brain tumor initiating cells.
Vora P; Seyfrid M; Venugopal C; Qazi MA; Salim S; Isserlin R; Subapanditha M; O'Farrell E; Mahendram S; Singh M; Bakhshinyan D; Chokshi C; McFarlane N; Dvorkin-Gheva A; Brown KR; Murty N; Moffat J; Bader GD; Singh SK
J Neurooncol; 2019 Jul; 143(3):417-428. PubMed ID: 31115870
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of miR16 in glioblastoma and glioblastoma stem cells: their correlation with proliferation, differentiation, metastasis and prognosis.
Tian R; Wang J; Yan H; Wu J; Xu Q; Zhan X; Gui Z; Ding M; He J
Oncogene; 2017 Oct; 36(42):5861-5873. PubMed ID: 28628119
[TBL] [Abstract][Full Text] [Related]
9. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.
Garner JM; Ellison DW; Finkelstein D; Ganguly D; Du Z; Sims M; Yang CH; Interiano RB; Davidoff AM; Pfeffer LM
PLoS One; 2015; 10(5):e0125838. PubMed ID: 25955030
[TBL] [Abstract][Full Text] [Related]
10. Involvement of miRNAs in the differentiation of human glioblastoma multiforme stem-like cells.
Aldaz B; Sagardoy A; Nogueira L; Guruceaga E; Grande L; Huse JT; Aznar MA; Díez-Valle R; Tejada-Solís S; Alonso MM; Fernandez-Luna JL; Martinez-Climent JA; Malumbres R
PLoS One; 2013; 8(10):e77098. PubMed ID: 24155920
[TBL] [Abstract][Full Text] [Related]
11. From the Cover: Neutralization of terminal differentiation in gliomagenesis.
Hu J; Ho AL; Yuan L; Hu B; Hua S; Hwang SS; Zhang J; Hu T; Zheng H; Gan B; Wu G; Wang YA; Chin L; DePinho RA
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14520-7. PubMed ID: 23918370
[TBL] [Abstract][Full Text] [Related]
12. High Podocalyxin levels promote cell viability partially through up-regulation of Annexin A2.
San IV; Prost G; Williams JA; Moss SE; Nuber UA
Biochem Biophys Res Commun; 2016 Sep; 478(2):573-9. PubMed ID: 27470587
[TBL] [Abstract][Full Text] [Related]
13. TGFβ-Responsive HMOX1 Expression Is Associated with Stemness and Invasion in Glioblastoma Multiforme.
Ghosh D; Ulasov IV; Chen L; Harkins LE; Wallenborg K; Hothi P; Rostad S; Hood L; Cobbs CS
Stem Cells; 2016 Sep; 34(9):2276-89. PubMed ID: 27354342
[TBL] [Abstract][Full Text] [Related]
14. ER stress and UPR activation in glioblastoma: identification of a noncanonical PERK mechanism regulating GBM stem cells through SOX2 modulation.
Peñaranda-Fajardo NM; Meijer C; Liang Y; Dijkstra BM; Aguirre-Gamboa R; den Dunnen WFA; Kruyt FAE
Cell Death Dis; 2019 Sep; 10(10):690. PubMed ID: 31534165
[TBL] [Abstract][Full Text] [Related]
15. SLC7A11 Overexpression in Glioblastoma Is Associated with Increased Cancer Stem Cell-Like Properties.
Polewski MD; Reveron-Thornton RF; Cherryholmes GA; Marinov GK; Aboody KS
Stem Cells Dev; 2017 Sep; 26(17):1236-1246. PubMed ID: 28610554
[TBL] [Abstract][Full Text] [Related]
16. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.
Alberti L; Losi L; Leyvraz S; Benhattar J
PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996
[TBL] [Abstract][Full Text] [Related]
17. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
[TBL] [Abstract][Full Text] [Related]
18. The effects of type I interferon on glioblastoma cancer stem cells.
Du Z; Cai C; Sims M; Boop FA; Davidoff AM; Pfeffer LM
Biochem Biophys Res Commun; 2017 Sep; 491(2):343-348. PubMed ID: 28728846
[TBL] [Abstract][Full Text] [Related]
19. Girdin maintains the stemness of glioblastoma stem cells.
Natsume A; Kato T; Kinjo S; Enomoto A; Toda H; Shimato S; Ohka F; Motomura K; Kondo Y; Miyata T; Takahashi M; Wakabayashi T
Oncogene; 2012 May; 31(22):2715-24. PubMed ID: 22020337
[TBL] [Abstract][Full Text] [Related]
20. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.
Liu Q; Nguyen DH; Dong Q; Shitaku P; Chung K; Liu OY; Tso JL; Liu JY; Konkankit V; Cloughesy TF; Mischel PS; Lane TF; Liau LM; Nelson SF; Tso CL
J Neurooncol; 2009 Aug; 94(1):1-19. PubMed ID: 19468690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
